Investigating how certain lymphomas resist treatment
Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling inHuman Lymphomas
This study is looking into why a specific type of lymphoma called ABC-DLBCL often doesn't respond well to treatments, and it's trying to find new ways to help patients by understanding the genetic changes in these tumors and how they interact with their environment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10873182 on NIH RePORTER |
What this research studies
This research focuses on understanding why the activated B cell subtype of diffuse large B cell lymphoma (ABC-DLBCL) often does not respond to current therapies. It examines the genetic mutations present in these tumors and how they interact with the surrounding lymphoid tumor microenvironment, which may contribute to treatment resistance. By studying these complex signaling pathways, the research aims to identify new therapeutic targets and develop combination treatments that could improve patient outcomes. Patients may benefit from insights that lead to more effective personalized therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with activated B cell subtype diffuse large B cell lymphoma who have not responded to standard therapies.
Not a fit: Patients with other types of lymphoma or those who have not been diagnosed with ABC-DLBCL may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with resistant forms of lymphoma.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other types of lymphomas, indicating potential for success in this approach.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Singh, Ankur — Georgia Institute of Technology
- Study coordinator: Singh, Ankur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.